Dermata Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRMA research report →
Range $6 – $6
Price Chart
About the company
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand.
- CEO
- Gerald T. Proehl
- IPO
- 2021
- Employees
- 9
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on DRMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.55M
- P/E
- -0.26
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.30
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -166.67%
- ROIC
- -246.61%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-7,773,598
- Net Income
- $-7,558,557+38.5%
- EPS
- $-8.16+89.8%
- OCF Growth
- +30.5%
- FCF Growth
- +30.5%
- 52W High
- $5.18
- 52W Low
- $0.95
- 50D MA
- $1.25
- 200D MA
- $1.44
- Beta
- 0.66
- RSI (14)
- 43
- Avg Volume
- 719.58K
No earnings-call transcripts are available for DRMA yet.
- Free Float
- 63.7%
- Shares Outstanding
- 4.02M
- Float Shares
- 2.56M
of shares held by institutions
7 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Geode Capital Management, LLC | 20.20K | ▼ 28.13K |
| Welch & Forbes LLC | 20.00K | 0 |
| State Street Corp | 18.75K | ▲ 18.75K |
| Ubs Group AG | 16.80K | ▼ 18.81K |
| Susquehanna International Group, Llp | 15.99K | ▲ 15.99K |
| Xtx Topco Ltd | 14.79K | ▲ 14.79K |
| Advisory Alpha, LLC | 10.00K | ▲ 10.00K |
| Tower Research Capital LLC (Trc) | 3.86K | ▲ 3.14K |
| Mcf Advisors LLC | 1.73K | 0 |
| Barclays PLC | 270 | ▲ 270 |
| Sbi Securities Co., Ltd. | 101 | 0 |
| Highline Wealth Partners LLC | 26 | ▲ 26 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 16, 26 | PROEHL GERALD T | other | 1,360,544 |
| Aug 16, 26 | PROEHL GERALD T | other | 1,360,544 |
| Aug 16, 26 | PROEHL GERALD T | other | 1,360,544 |
| Aug 16, 26 | PROEHL GERALD T | other | 170,068 |
| Aug 16, 26 | PROEHL GERALD T | other | 170,068 |
| Aug 16, 26 | PROEHL GERALD T | other | 170,068 |
| Aug 16, 26 | Van Hoose Kyri K. | other | 102,040 |
| Aug 16, 26 | Van Hoose Kyri K. | other | 102,040 |
| Aug 16, 26 | Van Hoose Kyri K. | other | 102,040 |
| Jun 16, 26 | Scott Kathleen D. | sell | 11 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DRMA coverage
Recent articles, reports, and earnings notes.
No research on DRMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRMA report →Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
accessnewswire.com · Aug 25
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
accessnewswire.com · Aug 21
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
accessnewswire.com · Aug 17
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
accessnewswire.com · Aug 11
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
accessnewswire.com · Aug 5
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
accessnewswire.com · May 13
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
accessnewswire.com · Apr 2
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
accessnewswire.com · Mar 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.